Importantly two PIKfyve inhibitors, apilimod and ESK981, have cleared phase 1 clinical trials (NCT02594384, NCT00875264)52,53, highlighting the rapid translational potential of targeting PIKfyve as a means to disrupt autophagy and lysosomal processes in cancers. Here, PIKFYVE is linked to cancer.